Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $56.48M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is 99283, emergency room visit (moderate) — 36% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
CONCORD, NC 28025
CONCORD, NC 28025
33aNPI1487866315assigned 05/04/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$56.48M
24GClaims750,684
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#8 of 92
Median peer was paid$11.47M
This provider vs. median4.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,519 | $5.10M | |
| 2019 | 95,579 | $5.66M | |
| 2020 | 68,322 | $3.92M | |
| 2021 | 105,852 | $7.31M | |
| 2022 | 109,039 | $9.65M | |
| 2023 | 133,735 | $11.66M | |
| 2024incomplete | 146,638 | $13.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 36% | 81,853 | 77,439 | $20.29M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 70,695 | 65,915 | $16.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 32,450 | 29,839 | $7.60M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 5.8% | 20,513 | 19,210 | $3.28M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 26,609 | 24,285 | $1.04M |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 21,983 | 20,743 | $782K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 27,581 | 24,150 | $674K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 30,413 | 28,225 | $580K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 8,906 | 8,528 | $509K |
| 80053 | Comprehensive metabolic panel | <1% | 51,077 | 47,215 | $508K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,886 | 55,202 | $491K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 974 | 925 | $490K |
109 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,351 | $287K |
| G0378 | Hospital observation service, per hour | <1% | 1,263 | $245K |
| 64483 | <1% | 1,069 | $234K | |
| 27096 | <1% | 1,556 | $185K | |
| J3490 | Unclassified drugs | <1% | 69,409 | $163K |
| 95714 | <1% | 260 | $162K | |
| 95700 | <1% | 245 | $120K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 625 | $118K |
| 81025 | <1% | 14,807 | $114K | |
| 59025 | Fetal non-stress test | <1% | 1,397 | $109K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,991 | $106K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,556 | $89K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,782 | $84K |
| 84484 | <1% | 8,910 | $82K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 935 | $80K |
| 83690 | <1% | 10,371 | $78K | |
| 81003 | <1% | 30,108 | $72K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,491 | $72K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,952 | $70K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,694 | $67K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,832 | $67K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 34,345 | $52K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,785 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,589 | $47K |
| 87430 | <1% | 2,927 | $46K | |
| 0002A | <1% | 853 | $46K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,350 | $45K |
| 0001A | <1% | 803 | $42K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 172 | $34K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,238 | $33K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 72 | $31K |
| 81001 | <1% | 7,916 | $30K | |
| 95951 | <1% | 49 | $25K | |
| 85027 | <1% | 3,253 | $22K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,912 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 972 | $20K |
| 83735 | <1% | 2,306 | $17K | |
| 87070 | <1% | 1,172 | $16K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 157 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,233 | $14K |
| 83605 | <1% | 1,226 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,778 | $12K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 4,531 | $10K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,341 | $6K |
| 87081 | <1% | 727 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 185 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 183 | $5K |
| 83880 | <1% | 133 | $5K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 45 | $5K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $4K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,784 | $4K |
| 84702 | <1% | 332 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 382 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 179 | $3K |
| 82803 | <1% | 231 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,203 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 14 | $3K |
| Q3014 | Telehealth originating site facility fee | <1% | 644 | $3K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,541 | $2K |
| 81002 | <1% | 714 | $2K | |
| 74018 | <1% | 52 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,364 | $2K |
| 87420 | <1% | 96 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,627 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 31 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 63 | $1K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,252 | $1K |
| 82962 | <1% | 849 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 389 | $994.07 |
| 97597 | <1% | 48 | $989.85 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 354 | $837.84 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 949 | $746.98 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 16 | $719.40 |
| 82657 | <1% | 27 | $682.72 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 434 | $640.86 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 208 | $601.66 |
| 73630 | <1% | 12 | $598.57 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 74 | $548.70 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 25 | $432.99 |
| 77072 | <1% | 12 | $428.16 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 1,793 | $427.93 |
| 87210 | <1% | 102 | $409.87 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 52 | $389.67 |
| 87486 | <1% | 12 | $377.29 | |
| 87581 | <1% | 12 | $377.29 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $375.36 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 184 | $351.10 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 277 | $329.65 |
| 85610 | <1% | 67 | $260.97 | |
| 82330 | <1% | 12 | $199.28 | |
| 80076 | <1% | 27 | $182.85 | |
| 80061 | Lipid panel | <1% | 13 | $153.05 |
| 94760 | <1% | 24 | $131.00 | |
| 96376 | <1% | 24 | $115.92 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 165 | $108.57 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 39 | $105.10 |
| 80051 | <1% | 12 | $100.56 | |
| 82075 | <1% | 13 | $65.77 | |
| 96127 | <1% | 12 | $65.52 | |
| 97602 | <1% | 18 | $65.05 | |
| 82947 | <1% | 12 | $57.28 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 27 | $41.16 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 44 | $25.23 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $13.72 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 14 | $8.81 |
| A9270 | Non-covered item or service | <1% | 303 | $0.05 |
| 91300 | 0% | 1,662 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.